Wang T, Tanaka M, Sato K
New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Antimicrob Agents Chemother. 1998 Feb;42(2):236-40. doi: 10.1128/AAC.42.2.236.
Mutations in the grlA and gyrA genes of 344 clinical strains of Staphylococcus aureus isolated in 1994 in Japan were identified by combinations of single-strand conformation polymorphism analysis, restriction fragment length analysis, and direct sequencing to identify possible relationships to fluoroquinolone resistance. Five types of single-point mutations and four types of double mutations were observed in the grlA genes of 204 strains (59.3%). Four types of single-point mutations and four types of double mutations were found in the gyrA genes of 188 strains (54.7%). Among them, the grlA mutation of TCC-->TTC or TAC (Ser-80-->Phe or Tyr) and the gyrA mutation of TCA-->TTA (Ser-84-->Leu) were principal, being detected in 137 (39.8%) and 121 (35.9%) isolates, respectively. The grlA point mutations of CAT-->CAC (His-77 [silent]), TCA-->CCA (Ser-81-->Pro), and ATA-->ATT (Ile-100 [silent]) were novel, as was the GAC-->GGC (Asp-73-->Gly) change in gyrA. A total of 15 types of mutation combinations within both genes were related to ciprofloxacin resistance (MIC > or = 3.13 microg/ml) and were present in 193 mutants (56.1%). Strains containing mutations in both genes were highly resistant to ciprofloxacin (MIC at which 50% of the isolates are inhibited [MIC50] = 50 microg/ml). Those with the Ser80-->Phe or Tyr alteration in grlA but wild-type gyrA showed a lower level of ciprofloxacin resistance (MIC50 < or = 12.5 microg/ml). Levofloxacin was active against 68 of 193 isolates (35.2%) with mutations at codon 80 of grlA in the presence or absence of a concomitant mutation at codon 73, 84, or 88 in gyrA (MIC < or = 6.25 microg/ml). The new fluoroquinolone DU-6859a showed good activity with 186 of 193 isolates (96.4%) for which the MIC was < or = 6.25 microg/ml.
通过单链构象多态性分析、限制性片段长度分析和直接测序相结合的方法,对1994年在日本分离出的344株金黄色葡萄球菌临床菌株的grlA和gyrA基因中的突变进行了鉴定,以确定其与氟喹诺酮耐药性之间可能存在的关系。在204株菌株(59.3%)的grlA基因中观察到5种单点突变和4种双突变。在188株菌株(54.7%)的gyrA基因中发现了4种单点突变和4种双突变。其中,grlA基因中TCC→TTC或TAC(Ser-80→Phe或Tyr)的突变以及gyrA基因中TCA→TTA(Ser-84→Leu)的突变最为主要,分别在137株(39.8%)和121株(35.9%)分离株中检测到。grlA基因中CAT→CAC(His-77[沉默突变])、TCA→CCA(Ser-81→Pro)和ATA→ATT(Ile-100[沉默突变])的单点突变,以及gyrA基因中GAC→GGC(Asp-73→Gly)的变化都是新发现的。两个基因中总共15种突变组合与环丙沙星耐药性(MIC≥3.13μg/ml)相关,存在于193个突变体中(56.1%)。两个基因都含有突变的菌株对环丙沙星高度耐药(50%的分离株被抑制时的MIC[MIC50]=50μg/ml)。grlA基因有Ser80→Phe或Tyr改变但gyrA基因为野生型的菌株对环丙沙星的耐药水平较低(MIC50≤12.5μg/ml)。在gyrA基因的第73、84或88位密码子存在或不存在伴随突变的情况下,左氧氟沙星对193株grlA基因第80位密码子有突变的分离株中的68株(35.2%)有活性(MIC≤6.25μg/ml)。新型氟喹诺酮DU-6859a对193株分离株中的186株(96.4%)显示出良好活性,其MIC≤6.25μg/ml。